Cargando…

Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome since obesity and insulin resistance are the main pathogenic contributors for both conditions. NAFLD carries increased risk of atherosclerosis and cardiovascular diseases. There is an urgent need to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janczyk, Wojciech, Socha, Piotr, Lebensztejn, Dariusz, Wierzbicka, Aldona, Mazur, Artur, Neuhoff-Murawska, Joanna, Matusik, Pawel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672084/ https://www.ncbi.nlm.nih.gov/pubmed/23702094 http://dx.doi.org/10.1186/1471-2431-13-85

Ejemplares similares

Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease
por: Trojanek, Joanna B., et al.
Publicado: (2020)

Non-alcoholic fatty liver disease and lipotoxicity
por: Wasilewska, Natalia, et al.
Publicado: (2021)

Prevalence and Significance of Autoantibody Seropositivity in Children with Wilson’s Disease
por: Jańczyk, Wojciech, et al.
Publicado: (2023)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods
por: Pawełczyk, Tomasz, et al.
Publicado: (2015)

Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2019)

Editorial: The broader aspects of non-alcoholic fatty liver disease in children
por: Mandato, Claudia, et al.
Publicado: (2022)

Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study
por: Irish, Ashley, et al.
Publicado: (2009)

Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation
por: Yang, Jinchunzi, et al.
Publicado: (2019)

Omega 3 Fatty Acids vs Omega 6 Fatty Acids
por: Feliu, María, et al.
Publicado: (2022)

Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation
por: Messamore, Erik, et al.
Publicado: (2016)

Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease
por: Alberti, Gigliola, et al.
Publicado: (2020)

Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)
por: Tobin, Derek, et al.
Publicado: (2018)

From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2021)

The effect of omega-3 fatty acids on alcohol-induced damage
por: Serrano, Maitane, et al.
Publicado: (2023)

Protocol for measuring intrahepatic triglyceride content in adults with non-alcohol fatty liver disease
por: Ezpeleta, Mark, et al.
Publicado: (2023)

Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the “Brazilian Omega Study” (BROS)—a randomized controlled trial
por: Batista, Ellencristina Silva, et al.
Publicado: (2021)

Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial
por: Arnardottir, Hildur, et al.
Publicado: (2021)

The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications
por: Viecelli, Andrea K., et al.
Publicado: (2015)

Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
por: Motta, Benedetta M., et al.
Publicado: (2019)

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis
por: Lee, Cheng-Han, et al.
Publicado: (2020)

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update
por: Hliwa, Aleksandra, et al.
Publicado: (2021)

Unraveling the Interplay between Nonalcoholic Fatty Liver Disease and Polycystic Ovary Syndrome in Adolescents: Pathogenesis, Prevalence, and Management Strategies
por: Półkośnik, Kinga, et al.
Publicado: (2023)

“A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven™) on outcome after major liver resection”
por: Linecker, Michael, et al.
Publicado: (2015)

Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease
por: Brown, Zachary J., et al.
Publicado: (2018)

Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: He, Xi-Xi, et al.
Publicado: (2016)

The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs
por: Yu, Le, et al.
Publicado: (2017)

Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials
por: Yan, Jian-Hui, et al.
Publicado: (2018)

Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease
por: Małecki, Paweł, et al.
Publicado: (2020)

Effect of a diet enriched with omega-6 and omega-3 fatty acids on the pig liver transcriptome
por: Szostak, Agnieszka, et al.
Publicado: (2016)

Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease
por: Wasilewska, Natalia, et al.
Publicado: (2018)

Effect of Omega-3 Fatty Acids on Telomeres—Are They the Elixir of Youth?
por: Ogłuszka, Magdalena, et al.
Publicado: (2022)

Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol
por: Chacón, Carla, et al.
Publicado: (2023)

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
por: Lu, Wenxia, et al.
Publicado: (2016)

Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD)
por: Brain, David, et al.
Publicado: (2020)

Fatty fish, marine omega-3 fatty acids, and incidence of heart failure
por: Levitan, Emily B., et al.
Publicado: (2010)

Predictive Value of Adiposity Level, Metabolic Syndrome, and Insulin Resistance for the Risk of Nonalcoholic Fatty Liver Disease Diagnosis in Obese Children
por: Prokopowicz, Zofia, et al.
Publicado: (2018)

Study protocol of OmegaROP-2 prospective study: expression of placental fatty acid receptors in preterm newborns with retinopathy of prematurity
por: Carré, Chloé, et al.
Publicado: (2023)

Dietary Omega-3 Fatty Acid Deficiency and High Fructose intake in the Development of Metabolic Syndrome Brain, Metabolic Abnormalities, and Non-Alcoholic Fatty Liver Disease
por: Simopoulos, Artemis P.
Publicado: (2013)

Omega-3 Fatty Acids and Inflammatory Processes
por: Calder, Philip C.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9q4r1rummni60k13op3b212fqt